UBS analyst AJ Rice lowered the firm’s price target on Acadia Healthcare (ACHC) to $28 from $31 and keeps a Buy rating on the shares. Payer issues and Medicaid volume softness are likely to continue, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare Reports Q3 Revenue Growth Amid Challenges
- Acadia Healthcare sentiment likely to worsen further, says Cantor Fitzgerald
- Acadia Healthcare COO Nasser Khan resigns
- Acadia Healthcare lowers FY25 adjusted EPS $2.35-$2.45 from $2.45-$2.65
- Acadia Healthcare taking ‘decisive action to drive improved performance’